Abstract
Introduction: Four out of ten major causes of death in the world are due to pulmonary pathologies where respiratory infections are in third place and in turn, are one of the main reasons for medical consultation. Interleukin (IL)-17 seems to have an important role in the immunopathogenesis of many diseases. Elevated levels of IL-17 in peripheral blood or other body fluids have been reported to be associated with metastases and infections. Likewise, the role that IL-17 has in the skin and intestinal pathology is clearly known, however;
its role within pulmonary pathologies is controversial yet. Objective: To describe the current knowledge on the role of IL-17 in inflammatory processes and pulmonary pathologies. Search Methodology: A bibliographic search of original and review papers was carried out in the MEDLINE and Science Direct database, in which 50 articles matched the inclusion criteria. Conclusions: The response involving IL-17 in the lung seems to be related to a good prognosis in the case of some bacterial pneumonia. Blocking the IL-17 signaling pathway in lung cancer could be beneficial and is considered as a potential therapeutic target under these conditions, so studies on this subject must be continued to better understand the true role of this protein in every athologic lung condition. MÉD.UIS.2021;34(1): 55-62.
References
Organización Mundial de la salud. No Title [Internet]. Estimaciones de salud global por causa, edad, sexo, por país y por región.
Mcaleer JP, Kolls JK. Directing traffic: IL-17 and IL-22 coordinate pulmonary immune defense. Immunol Rev. 2014;260(1):129-44
Happel KI, Dubin PJ, Zheng M, Ghilardi N, Lockhart C, Quinton LJ, et al. Divergent roles of IL-23 and IL-12 in host defense against Klebsiella pneumoniae. J Exp Med. 2005;202(6):761–9.
Rudner XL, Happel KI, Young EA, Shellito JE. Interleukin-23 (IL-23)-IL-17 Cytokine Axis in Murine Pneumocystis carinii Infection. Infect Immun. 2007;75(6):3055–61.
Ye P, Rodriguez FH, Kanaly S, Stocking KL, Schurr J, Schwarzenberger P, et al. Requirement of interleukin 17 receptor signaling for lung CXC chemokine and granulocyte olonystimulating factor expression, neutrophil recruitment, and host defense. J Exp Med. 2001;194(4):519–27.
Huang W, Na L, Fidel PL, Schwarzenberger P. Requirement of Interleukin‐17A for Systemic Anti–Candida albicans Host Defense in Mice. J Infect Dis. 2004;190(3):624–31.
Kuwabara T, Ishikawa F, Kondo M, Kakiuchi T. The Role of IL-17 and Related Cytokines in Inflammatory Autoimmune Diseases. Mediators Inflamm. 2017;2017:3908061. PubMed MID: 28316374; PMC PMCID: PMC5337858.
Gaffen SL. Recent advances in the IL-17 cytokine family. Curr Opin Immuno. 2011;23(5):613-9.
Onishi RM, Gaffen SL. Interleukin-17 and its target genes: Mechanisms of interleukin-17 function in disease. Immunology. 2010 Mar;129(3):311-21.
Amatya N, Garg A V., Gaffen SL. IL-17 Signaling: The Yin and the Yang. Trends Immunol. 2017;38(5):310-322.
Vélez-Marín VM, París-Ángel SC, García-Moreno LF. Interleuquina-17: características, vías de diferenciación, señalización y funciones biológicas. Iatreia. 2007;20(2):186-95.
He G, Zhang B, Zhang B, Qiao L, Tian Z, Zhai G, et al. Th17 cells and IL-17 are increased in patients with brain metastases from the primary lung cancer. Chinese J Lung Cancer. 2013;16(9):476–81.
Gaffen SL, Jain R, Garg AV, Cua DJ. The IL-23-IL-17 immune axis: from mechanisms to therapeutic testing. Nat Rev Immunol. 2014;14(9):585-600.
Seon HC, Park H, Dong C. Act1 adaptor protein is an immediate and essential signaling component of interleukin-17 receptor. J Biol Chem. 2006;281(47):35603–7.
Fu ZW, Zhang ZY, Ge HY. Mesenteric injection of adipose-derived mesenchymal stem cells relieves experimentally-induced colitis in rats by regulating Th17/Treg cell balance. Am J ransl Res. 2018;10(1):54–66.
Egwuagu CE. STAT3 in CD4+ T helper cell differentiation and inflammatory diseases. Cytokine. 2009;47(3):149-56.
Lee SY, Lee SH, Yang EJ, Kim EK, Kim JK, Shin DY, Cho ML. Metformin Ameliorates Inflammatory Bowel Disease by Suppression of the STAT3 Signaling Pathway and Regulation of the between Th17/Treg Balance. PLoS One. 2015;10(9):e0135858.
Yu H, Pardoll D, Jove R. STATs in cancer inflammation and immunity: a leading role for STAT3. Nat Rev Cancer. 2009;9(11):798-809.
Jin W, Dong C. IL-17 cytokines in immunity and inflammation. Emerg Microbes Infect. 2013;2(9):e60.
Dong C. TH17 cells in development: an updated view of their molecular identity and genetic programming. Nat Rev Immunol. 2008;8(5):337-48.
Sheng W, Yang F, Zhou Y, Yang H, Low PY, Kemeny DM, et al. STAT5 programs a distinct subset of GM-CSF-producing T helper cells that is essential for autoimmune euroinflammation. Cell Res. 2014;24(12):1387–402.
Li Z, Li D, Tsun A, Li B. FOXP3+ regulatory T cells and their functional regulation. Cell Mol Immunol. 2015;12(5):558-65.
Goodman WA, Young AB, McCormick TS, Cooper KD, Levine AD. Stat3 Phosphorylation Mediates Resistance of Primary Human T Cells to Regulatory T Cell Suppression. J Immunol. 2011;186(6):3336–45.
Geremia A, Jewell DP. The IL-23/IL-17 pathway in inflammatory bowel disease. Expert Rev Gastroenterol Hepatol. 2012;6(2):223- 37.
Iwakura Y, Ishigame H, Saijo S, Nakae S. Functional specialization of interleukin-17 family members. Immunity. 2011;34(2):149-62.
Schmidt EGW, Larsen HL, Kristensen NN, Poulsen SS, Pedersen AML, Claesson MH, et al. TH17 cell induction and effects of IL17A and IL-17F blockade in experimental colitis. Inflamm Bowel Dis. 2013;19(8):1567–76.
Al-Ramli W, Préfontaine D, Chouiali F, Martin JG, Olivenstein R, Lemière C, et al. T(H)17-associated cytokines (IL-17A and IL-17F) in severe asthma. J Allergy Clin Immunol. 2009;123(5):1185-7.
Deng Y, Chang C, Lu Q. The Inflammatory Response in Psoriasis: a Comprehensive Review. Clin Rev Allergy Immunol. 2016;50(3):377-89.
Hueber W, Patel DD, Dryja T, Wright AM, Koroleva I, Bruin G, et al. Effects of AIN457, a Fully Human Antibody to Interleukin17A, on Psoriasis, Rheumatoid Arthritis, and Uveitis. Sci Transl Med. 2010;2(52):52ra72.
Khader SA, Gaffen SL, Kolls JK. Th17 cells at the crossroads of innate and adaptive immunity against infectious diseases at the mucosa. Mucosal Immunol. 2009;2(5):403-11.
Tang H, Pang S, Wang M, Xiao X, Rong Y, Wang H, et al. TLR4 Activation Is Required for IL-17-Induced Multiple Tissue Inflammation and Wasting in Mice. J Immunol. 2010;185(4):2563–9.
Misiak A, Wilk MM, Raverdeau M, Mills KHG. IL-17–Producing Innate and Pathogen-Specific Tissue Resident Memory γδ T Cells Expand in the Lungs of Bordetella pertussis– Infected Mice. J Immunol. 2017;198(1):363–74.
Dubin PJ, Kolls JK. IL-23 mediates inflammatory responses to mucoid Pseudomonas aeruginosa lung infection in mice. Am J Physiol Lung Cell Mol Physiol. 2007;292(2): L519-28.
Singh RP, Hasan S, Sharma S, Nagra S, Yamaguchi DT, Wong DTW, et al. Th17 cells in inflammation and autoimmunity. Autoimmun Rev. 2014;13(12):1174–81.
Jurado JO, Pasquinelli V, Alvarez IB, Peña D, Rovetta AI, Tateosian NL, et al. IL-17 and IFN-γ expression in lymphocytes from patients with active tuberculosis correlates with the severity of the disease. J Leukoc Biol. 2012;91(6):991–1002.
Fukui M, Shinjo K, Umemura M, Shigeno S, Harakuni T, Arakawa T, et al. Enhanced effect of BCG vaccine against pulmonary Mycobacterium tuberculosis infection in mice with lung Th17 response to mycobacterial heparin-binding hemagglutinin adhesin antigen. Microbiol Immunol. 2015;59(12):735–43.
Wang J, Li F, Wei H, Lian Z-X, Sun R, Tian Z. Respiratory influenza virus infection induces intestinal immune injury via microbiota-mediated Th17 cell–dependent inflammation. J xp Med. 2014;211(12):2397–410.
Ettinger DS, Wood DE, Aisner DL, Akerley W, Bauman J, Chirieac LR, et al. Non–Small Cell Lung Cancer, Version 5.2017, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Cancer Netw. 2017;15(4):504–35.
Travis WD, Brambilla E, Nicholson AG, Yatabe Y, Austin JHM, Beasley MB, et al. The 2015 World Health Organization Classification of Lung Tumors: Impact of Genetic, Clinical and Radiologic Advances Since the 2004 Classification. J Thorac Oncol. 2015;10(9):1243–60.
Wu F, Xu J, Huang Q, Han J, Duan L, Fan J, et al. The role of interleukin-17 in Lung Cancer. Mediators Inflamm. 2016;2016:8494079.
Joerger M, Finn SP, Cuffe S, Byrne AT, Gray SG. The IL-17-Th1/ Th17 pathway: an attractive target for lung cancer therapy? Expert Opin Ther Targets. 2016;20(11):1339–56.
aabachi W, Amor A ben, Kaabachi S, Rafrafi A, Tizaoui K, Hamzaoui K. Interleukin-17A and -17F genes polymorphisms in lung cancer. Cytokine. 2014;66(1):23–9.
Wang H, Zhang Y, Liu Z, Zhang Y, Zhao H, Du S. The IL-17A G-197A and IL-17F 7488T/C polymorphisms are associated with increased risk of cancer in Asians: A meta-analysis. Drug Des Devel Ther. 2015;9:5159–68.
Chang SH, Mirabolfathinejad SG, Katta H, Cumpian AM, Gong L,no MS, et al. T helper 17 cells play a critical pathogenic rolen lung cancer. Proc Natl Acad Sci. 2014;111(15):5664–9.
Carmi Y, Rinott G, Dotan S, Elkabets M, Rider P, Voronov E, et al. Microenvironment-Derived IL-1 and IL-17 Interact in the Control of Lung Metastasis. J Immunol. 2011;186(6):3462–71.
Reppert S, Boross I, Koslowski M, Türeci Ö, Koch S, Lehr HA, et al. A role for T-bet-mediated tumour immune surveillance in anti-IL 17A treatment of lung cancer. Nat Commun. 2011;2:600.
Reppert S, Koch S, Finotto S. IL-17A is a central regulator of lung tumor growth. Oncoimmunology. 2012;1(5):783–5.
Qian X, Chen H, Wu X, Hu L, Huang Q, Jin Y. Interleukin-17 acts as double-edged sword in anti-tumor immunity and tumorigenesis. Cytokine. 2017;89:34–44.
Losada PX, Perdomo-Celis F, Castro M, Salcedo C, Salcedo A, DeLaura I, et al. Locally-secreted interleukin-6 is related with
radiological severity in smear-negative pulmonary tuberculosis. Cytokine. 2020;127:154950. earl JE, Sakamoto K, Gilmartin L, Bell GK, JelleyGibbs DM, et al. IL-23 Compensates for the absence of IL-12p70 and is essential for the IL-17 response during tuberculosis but
is dispensable for Protection and antigen-Specific IFN- gamma responses if IL-12p70 is available. J Immunol. 2005;175(2):788–95.
This work is licensed under a Creative Commons Attribution 4.0 International License.
Copyright (c) 2021 Médicas UIS